Dr Yu Wang
Position:
- Research Associate, Genomic Medicine, Cleveland Clinc, Lerner Research Institute
Biography:
I investigate the function of androgens and its crosstalk with PI3K/AKT pathways in prostate, breast, and other endocrine-related cancers. My special interest is to elucidate the mechanisms for CRPC development and progression,providing pre-clinical guidelines for alternative treatment.
Best publications:
- Wang Y, Kreisberg JI, Bedolla R, Mikhailova M, deVere White RW, and Ghosh PM. A 90kDa fragment of Filamin A promotes Casodex-induced growth inhibition in Casodex-resistant androgen-receptor positive C4-2 prostate cancer cells. Oncogene 2007 Sep 6; 26(41): 6061-70. 34
- Wang Y, Kreisberg JI, and Ghosh PM. Cross-talk between the androgen receptor and the phosphatidylinositol 3-kinase/AKT pathway in androgen-independent prostate cancer. Cur Cancer Drug Targ, 2007; 7: 325-334. 60
- Wang Y, Mikhailova M, Bose S, Pan CX, deVere White RW, and Ghosh PM. Regulation of androgen receptor transcriptional activity by rapamycin in prostate cancer cell proliferation and survival. Oncogene. 2008 Nov 27; 27(56): 7106-17. 32
- Wang Y, Romigh T, He X, Orloff MS, Silverman RH, Heston WD, Eng C. Resveratrol regulates the PTEN/AKT pathway through androgen receptor-dependent and -independent mechanisms in prostate cancer cell lines. Hum Mol Genet. 2010 Nov 15; 19(22): 4319-29. 12
- Wang Y, Romigh T, He X, Tan MH, Orloff MS, Silverman RH, Heston WD, Eng C. Differential regulation of PTEN expression by androgen receptor in prostate and breast cancers. Oncogene. 2011 Oct 20; 30 (42): 4327-38 3
Cancer Genetics, Endocrinology, Androgen Receptor, AKT, PTEN.
